198 related articles for article (PubMed ID: 20337633)
1. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis.
Turiel M; Tomasoni L; Sitia S; Cicala S; Gianturco L; Ricci C; Atzeni F; De Gennaro Colonna V; Longhi M; Sarzi-Puttini P
Cardiovasc Ther; 2010 Oct; 28(5):e53-64. PubMed ID: 20337633
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients.
Turiel M; Atzeni F; Tomasoni L; de Portu S; Delfino L; Bodini BD; Longhi M; Sitia S; Bianchi M; Ferrario P; Doria A; De Gennaro Colonna V; Sarzi-Puttini P
Rheumatology (Oxford); 2009 Jul; 48(7):834-9. PubMed ID: 19465588
[TBL] [Abstract][Full Text] [Related]
3. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients.
Sidiropoulos PI; Siakka P; Pagonidis K; Raptopoulou A; Kritikos H; Tsetis D; Boumpas DT
Scand J Rheumatol; 2009; 38(1):6-10. PubMed ID: 18991190
[TBL] [Abstract][Full Text] [Related]
4. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study.
Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A
Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602
[TBL] [Abstract][Full Text] [Related]
5. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
[TBL] [Abstract][Full Text] [Related]
6. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis.
Kerekes G; Soltész P; Szucs G; Szamosi S; Dér H; Szabó Z; Csáthy L; Váncsa A; Szodoray P; Szegedi G; Szekanecz Z
Isr Med Assoc J; 2011 Mar; 13(3):147-52. PubMed ID: 21608334
[TBL] [Abstract][Full Text] [Related]
7. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis.
Atzeni F; Sarzi-Puttini P; Sitia S; Tomasoni L; Gianturco L; Battellino M; Boccassini L; De Gennaro Colonna V; Marchesoni A; Turiel M
J Rheumatol; 2011 Aug; 38(8):1661-4. PubMed ID: 21632673
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
[TBL] [Abstract][Full Text] [Related]
9. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.
Sandoo A; Dimitroulas T; Toms TE; Hodson J; Veldhuijzen van Zanten JJ; Smith JP; Kitas GD
Clin Biochem; 2012 Nov; 45(16-17):1399-403. PubMed ID: 22820438
[TBL] [Abstract][Full Text] [Related]
10. Automated radiofrequency-based US measurement of common carotid intima-media thickness in RA patients treated with synthetic vs synthetic and biologic DMARDs.
Naredo E; Möller I; Corrales A; Bong DA; Cobo-Ibáñez T; Corominas H; Garcia-Vivar ML; Macarrón P; Navio T; Richi P; Iagnocco A; Garrido J; Martínez-Hernández D
Rheumatology (Oxford); 2013 Feb; 52(2):376-81. PubMed ID: 23065319
[TBL] [Abstract][Full Text] [Related]
11. Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis.
Ciftci O; Yilmaz S; Topcu S; Caliskan M; Gullu H; Erdogan D; Pamuk BO; Yildirir A; Muderrisoglu H
Atherosclerosis; 2008 Jun; 198(2):332-7. PubMed ID: 18164712
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis.
Di Franco M; Spinelli FR; Metere A; Gerardi MC; Conti V; Boccalini F; Iannuccelli C; Ciciarello F; Agati L; Valesini G
Mediators Inflamm; 2012; 2012():347268. PubMed ID: 22927708
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M
Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
[TBL] [Abstract][Full Text] [Related]
16. Endothelial dysfunction, intima-media thickness and coronary reserve in relation to risk factors and Framingham score in patients without clinical atherosclerosis.
Campuzano R; Moya JL; García-Lledó A; Tomas JP; Ruiz S; Megías A; Balaguer J; Asín E
J Hypertens; 2006 Aug; 24(8):1581-8. PubMed ID: 16877961
[TBL] [Abstract][Full Text] [Related]
17. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis.
Kerekes G; Soltész P; Dér H; Veres K; Szabó Z; Végvári A; Shoenfeld Y; Szekanecz Z
Ann N Y Acad Sci; 2009 Sep; 1173():814-21. PubMed ID: 19758233
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Treatments for Rheumatoid Arthritis on Endothelial Dysfunction Evaluated by Flow-Mediated Vasodilation in Patients with Rheumatoid Arthritis.
Kotani K; Miyamoto M; Ando H
Curr Vasc Pharmacol; 2017; 15(1):10-18. PubMed ID: 27739363
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia.
Machado-Alba JE; Ruiz AF; Machado-Duque ME
Int J Clin Pract; 2016 Jun; 70(6):506-11. PubMed ID: 27238964
[TBL] [Abstract][Full Text] [Related]
20. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab.
Gonzalez-Juanatey C; Llorca J; Sanchez-Andrade A; Garcia-Porrua C; Martin J; Gonzalez-Gay MA
Clin Exp Rheumatol; 2006; 24(3):309-12. PubMed ID: 16870100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
